^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR L858R + PD-L1 expression

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor, PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Entrez ID:
    1956; 29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    Real-world data of atezolizumab in combination with bevacizumab, and platinum-based chemotherapy for EGFR-mutant metastatic non-small cell lung cancer patients after failure of EGFR tyrosine kinase inhibitors. (ELCC 2023)
    Before the combination therapy, 24 (66.7%) patients and 11 (30.6%) patients have taken osimertinib and anti-angiogenesis, respectively. There were no significant differences in response rates and PFS between patients with and without malignant pleural effusion, liver, or brain metastasis. Conclusions The combination treatment of atezolizumab, bevacizumab, pemetrexed, and cisplatin/carboplatin provided favorable efficacy in EGFR mutation-positive NSCLC after TKI failure, and higher PD-L1 expression (≧ 1%) was associated with longer PFS.
    Clinical • Combination therapy • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L858R + PD-L1 expression
    |
    Avastin (bevacizumab) • cisplatin • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • carboplatin • pemetrexed